CRISPR Therapeutics AG (CRSP) vs Recursion Pharmaceuticals, Inc. (RXRX)
A side-by-side comparison of CRISPR Therapeutics AG and Recursion Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 2, 2026. Differences are shown without an overall score or investment verdict.
CRSP
CRISPR Therapeutics AG
$55.43HealthcareDelayed quote: Oct 2, 2026, 4:00 PM EDT
RXRX
Recursion Pharmaceuticals, Inc.
$4.12HealthcareDelayed quote: Oct 2, 2026, 4:00 PM EDT
Total return — CRSP vs RXRX
growth of $100 · dividends reinvested · last 5yCRSP -55.2% (-14.8%/yr)RXRX -77.4% (-25.7%/yr)CRSP compounded faster over this window
CRSP RXRX
CRSP vs RXRX: by the numbers
- •CRSP is the larger company ($5.35B vs $2.16B market cap).
- •Both run net losses; RXRX's is the smaller (-945.92% vs -3368.72% net margin).
- •RXRX grew revenue faster over the past five years (45.50% vs 37.32% CAGR).
Metrics side by side
Valuation
| Metric | CRSP | RXRX |
|---|---|---|
| P/S ratio | 399.21 | 39.41 |
| P/B ratio | 3.06 | 2.36 |
Profitability
| Metric | CRSP | RXRX |
|---|---|---|
| Gross margin | -6537.01% | -61.96% |
| Operating margin | -16191.40% | -867.87% |
| Net margin | -3368.72% | -945.92% |
| ROE | -25.83% | -56.71% |
| ROIC | -21.12% | -49.78% |
Growth (annualized)
| Metric | CRSP | RXRX |
|---|---|---|
| Revenue CAGR (5Y) | 37.32% | 45.50% |
| Total return CAGR (5Y) | -13.01% | -28.56% |
Frequently asked
- Which has grown faster, CRSP or RXRX?
- Over the past five years, RXRX grew revenue faster — CRSP at a 37.32% CAGR versus RXRX at 45.50%.
- How have CRSP and RXRX total returns compared?
- Over the past 5 years, CRSP delivered -13.01% and RXRX delivered -28.56% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
CRISPR Therapeutics AG ROERecursion Pharmaceuticals ROECRISPR Therapeutics AG operating marginRecursion Pharmaceuticals operating marginCRISPR Therapeutics AG revenue growthRecursion Pharmaceuticals revenue growthCRISPR Therapeutics AG free cash flowRecursion Pharmaceuticals free cash flow
CRISPR Therapeutics AG & Recursion Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 2, 2026.